Commission Implementing Regulation (EU) 2018/1266 of 20 September 2018 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances 1-decanol, 6-benzyladenine, aluminium sulfate, azadirachtin, bupirimate, carboxin, clethodim, cycloxydim, dazomet, diclofop, dithianon, dodine, fenazaquin, fluometuron, flutriafol, hexythiazox, hymexazol, indolylbutyric acid, isoxaben, lime sulphur, metaldehyde, paclobutrazol, pencycuron, sintofen, tau-fluvalinate and tebufenozide (Text with EEA relevance.)

• CELEX: Implementing Regulation (EU) 2018/1266
• Articles: 3

Article 1

The Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .

Schedules & Appendices

ANNEX

ANNEX

Part A of the Annex to Implementing Regulation (EU) No 540/2011 is amended as follows:

(1)

in the sixth column, expiration of approval, of row 316, Cycloxydim, the date is replaced by ‘31 May 2023’;

(2)

in the sixth column, expiration of approval, of row 317, 6-Benzyladenine, the date is replaced by ‘31 May 2024’;

(3)

in the sixth column, expiration of approval, of row 322, Hymexazol, the date is replaced by ‘31 May 2023’;

(4)

in the sixth column, expiration of approval, of row 323, Dodine, the date is replaced by ‘31 May 2024’;

(5)

in the sixth column, expiration of approval, of row 326, Indolylbutyric acid, the date is replaced by ‘31 May 2023’;

(6)

in the sixth column, expiration of approval, of row 328, Tau-fluvalinate, the date is replaced by ‘31 May 2024’;

(7)

in the sixth column, expiration of approval, of row 329, Clethodim, the date is replaced by ‘31 May 2023’;

(8)

in the sixth column, expiration of approval, of row 330, Bupirimate, the date is replaced by ‘31 May 2024’;

(9)

in the sixth column, expiration of approval, of row 333, 1-decanol, the date is replaced by ‘31 May 2024’;

(10)

in the sixth column, expiration of approval, of row 334, Isoxaben, the date is replaced by ‘31 May 2024’;

(11)

in the sixth column, expiration of approval, of row 335, Fluometuron, the date is replaced by ‘31 May 2024’;

(12)

in the sixth column, expiration of approval, of row 337, Carboxin, the date is replaced by ‘31 May 2023’;

(13)

in the sixth column, expiration of approval, of row 339, Dazomet, the date is replaced by ‘31 May 2023’;

(14)

in the sixth column, expiration of approval, of row 340, Metaldehyde, the date is replaced by ‘31 May 2023’;

(15)

in the sixth column, expiration of approval, of row 341, Sintofen, the date is replaced by ‘31 May 2024’;

(16)

in the sixth column, expiration of approval, of row 342, Fenazaquin, the date is replaced by ‘31 May 2023’;

(17)

in the sixth column, expiration of approval, of row 343, Azadirachtin, the date is replaced by ‘31 May 2024’;

(18)

in the sixth column, expiration of approval, of row 344, Diclofop, the date is replaced by ‘31 May 2023’;

(19)

in the sixth column, expiration of approval, of row 345, Lime sulphur, the date is replaced by ‘31 May 2024’;

(20)

in the sixth column, expiration of approval, of row 346, Aluminium sulfate, the date is replaced by ‘31 May 2024’;

(21)

in the sixth column, expiration of approval, of row 348, Paclobutrazol, the date is replaced by ‘31 May 2023’;

(22)

in the sixth column, expiration of approval, of row 349, Pencycuron, the date is replaced by ‘31 May 2024’;

(23)

in the sixth column, expiration of approval, of row 350, Tebufenozide, the date is replaced by ‘31 May 2024’;

(24)

in the sixth column, expiration of approval, of row 351, Dithianon, the date is replaced by ‘31 May 2024’;

(25)

in the sixth column, expiration of approval, of row 352, Hexythiazox, the date is replaced by ‘31 May 2024’;

(26)

in the sixth column, expiration of approval, of row 353, Flutriafol, the date is replaced by ‘31 May 2024’.